Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmalabs Ltd are among the other gainers in the BSE's 'A' group today, 06 February 2025.

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is ...

While the controversy − and legal battles − heat up over New Jersey's affordable housing mandate, an explosion of ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Exploring Analgesics as a Key Painkiller Types & Their Role in Pain ReliefUnited States, New York, Feb. 04, 2025 (GLOBE ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...